



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 03-01-2012.

Umme Salma
Assistant Director,
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT AND INDUSTRIAL DESIGNS
FOR THE WEEK-ENDING OF 23/12/2011 TO BE PUBLISHED. IN
THE 09/01/2012 GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Sabir Gul)
Controller of Patents
& Registrar of Designs
Ph: 99215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

19-12-2011

917/201	Boehringer ingelheim international GmbH Germany (Priority 21-12-2010 Europe)	“New benzylic oxindole pyrimidines”
918/2011	Boehringer ingelheim international GmbH Germany (Priority 21-12-2010 Europe)	“New triazolylphenyl sulfonamides as serine/threonine kinase inhibitors”
919/2011	Urea Casale SA. Switzerland (Priority 23-12-2010 Europe)	“Pneumatic high-frequency turbine vibrator suitable for use in a prilling bucket”
920/2011	BASF SE Germany (Priority 21-12-2010 Europe)	“Process for preparing formic acid by reacting carbon dioxide with hydrogen”
921/2011	IRM LLC Bermuda (Priority 20-12-2010 USA)	“Compositions and methods for modulating fxr”

20-12-2011

922/2011	Agra Quest, Inc. USA (Priority 21-12-2010 USA)	“Sandpaper mutants of bacillus and methods of their use to enhance plant growth, promote plant health and control diseases”
923/2011	Panacea Biotce Limited India (Priority 20-12-2010 India)	“Recombinant respiratory syncytial virus plasmids and vaccines”
924/2011	Abbott Laboratories USA (Priority 22-12-2010 USA)	“Half immunoglobulin binding proteins and uses thereof”
925/2011	Abbott Laboratories USA (Priority 22-12-2010 USA)	“Tri-variable domain binding proteins and uses thereof”

926/2011 Novartis AG "Di/tri-aza-spiro-C9-c11alkanes"
Switzerland
(Priority 22-12-2010 India)

21-12-2011

927/2011 AstraZeneca AB, "Compounds and their use as bace
Sweden inhibitors"
(Priority 22-12-2010 USA)

928/2011 Pfizer Inc "Glucagon receptor modulators"
USA
(Priority 23-12-2010 USA)

929/2011 Dow agro Sciences LLC "Methods to determine zygoty in a
USA bulked sample"
(Priority 29-12-2010 USA)

930/2011 Eli Lilly and company "PI3 Kinase/mtor Dual Inhibitor"
USA
(Priority 14-01-2011 USA)

931/2011 Sanofi "Robo1-fc fusion protein for use in the
France treatment of hepatocarcinoma"
(Priority 23-12-2010 France)

932/2011 Commonwealth Scientific and "Electrode and electrical storage device
Industrial Research Organisation for lead-acid system"
Australia
The Furukawa Battery Co., Ltd
Japan
(Priority 21-12-2010 Japan)

22-12-2011

933/2011 H. Lundbeck A/S "Bicyclo[3.2.1]octyl amide derivatives
Denmark and uses of same"
(Priority 22-12-2010 USA)

934/2011 Purdue Pharma L.P. "Encased Tamper Resistant Controlled
USA Release Dosage Forms"
(Priority 22-12-2010 USA)

935/2011 Dy Star Colours Deutschland "Disazo dyes, preparation and use"
GmbH
Germany
(Priority 24-12-2010 Germany)

- | | | |
|----------|--|---|
| 936/2011 | Sumitomo Chemical Co. Ltd.
Japan
(Priority 27-12-2010 Japan) | “Hydrate of sulfonylurea compounds,
process for producing the same and
suspension formulation containing the
same” |
| 937/2011 | Leo Pharma A/S
Denmark
(Priority 22-12-2010 USA) | “Ingenol-3-acylates iii and ingenol-3-
carbamates” |

23-12-2011

- | | | |
|----------|---|---|
| 938/2011 | Loris Bellini S.r.l
Italy
(Priority 27-12-2010 Italy) | “Machine and procedure for the dyeing
of reels of yarn and/or textile fibres
wound on packages” |
|----------|---|---|

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

794/2005 Wyeth Research Ireland
Limited
Ireland

“Process of Producing ANTI/A beta antibodies”
C12P 21/08,

141303

An improved system for large scale production of proteins and/or a-Beta in cell culture, particularly in media characterized by one or more of: i) a cumulative amino acid concentration greater than about 70 mM, ii) a molar cumulative glutamine to cumulative asparagine ratio of less than about 2; iii) a molar cumulative glutamine to cumulative total amino acid ratio of less than about 0.2; iv) a molar cumulative inorganic ion to cumulative total amino acid ratio between about 0.4 to 1; or v) a combined cumulative glutamine and cumulative asparagine concentration between about 16 and 36 mM, is provided. The use of such a system allows high levels of a- Beta production and lessens accumulation of certain undesirable factors such as ammonium and/or lactate. Additionally, culture methods including a temperature shift, typically including a decrease in temperature when the culture has reached about 20-80% of its maximal cell density, are provided. Alternatively or additionally, the present invention provides methods such that, after reaching a peak, lactate and/or ammonium levels in the culture decrease over time.

795/2005 Wyeth Research Ireland
Limited
Ireland

“Process of Producing TNFR-Ig”

C12P 21/08, C12N 5/06

141304

An improved system for large scale production of proteins and/or a-Beta in cell culture, particularly in media characterized by one or more of: i) a cumulative amino acid concentration greater than about 70 mM, ii) a molar cumulative glutamine to cumulative asparagine ratio of less than about 2; iii) a molar cumulative glutamine to cumulative total amino acid ratio of less than about 02; iv) a molar cumulative inorganic ion to cumulative total amino acid ratio between about 0.4 to 1; or v) a combined cumulative glutamine and cumulative asparagine concentration between about 16 and 36 mM, is provided. The use of such a system allows high levels of a- Beta production and lessens accumulation of certain undesirable factors such as ammonium and/or lactate. Additionally, culture methods including a temperature shift, typically including a decrease in temperature when the culture has reached about 20-80% of it maximal cell density, are provided. Alternatively or additionally, the present invention provides methods such that, after reaching a peak, lactate and/or ammonium levels in the culture decrease over time.


165/2007 Eisai R&D Management Co.,
Limited
Japan

“4-(3-Benzoylamino-phenyl)-6,7-dimethoxy-2-mehtylaminoquinazolin compound, pharmaceutical composition containing it for use in relieving itch caused by atopic disease”

CO7D 239/84, A61K 31/517, A61P 17/04

141305

A compound represented by the following formula (I), hydrate thereof, can effectively relieve itch caused by atopic disease or the like:



wherein R represents hydroxyl, C₁₋₆ alkoxy optionally substituted with C₁₋₆ alkoxy, or amino optionally substituted with C₁₋₆ alkyl.


892/2007 Chiesi Farmaceutici S.p.A.
Italy

“3-[(N-phenyl-N-benzyl)carbamoyloxy]-1-(2-oxo-
thiophen-2-ylethyl)-1-
azoniabicyclo [2.2.2] octane”

C07D 453/02, A61K 45/06, A61P 11/00

141306

The invention relates to a quinuclidine compound of formula (Ic):



wherein

R₁, in position 2 or 3, is selected from the group consisting of F, C₁, Br and I;

R₂ is 3,4,5-trifluorophenyl, 3,4-difluorophenyl, 2-hydroxyphenyl or 4-hydroxyphenyl;

X⁻ is a pharmaceutically acceptable anion;

are useful for the treatment and therapy of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic bronchitis, cough and emphysema.


682/2009 Pfizer Inc.
USA

“4b-benzyl-6,7-dihydroxy-6-methyl-N-(2-methylpyridin-3-yl)-10-oxo-7-phenyl-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-2-carboxamide compound and composition”

C07D 213/75

141307

The present invention is directed to the compound of Formula I:



which is the modulator of the glucocorticoid receptor. The compound of the invention is useful in the treatment of conditions mediated by glucocorticoid receptor activity.


545/2010 Eli Lilly and Company
USA

“Trans-4-[[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid”

C07D 403/12

141308

Compound of formula



NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS

S. No.	Design No.	Title & Class	Inventor
<u>19-12-2011</u>			
1	15990	Heavy Duty Foot Washer (Class-)	Bold International FZCO
2	15991	Square Foot Washer (Class-)	Bold International FZCO
3	15992	Combi Foot Washer (Class-)	Bold International FZCO
4	15993	Cabinet Foot Washer (Class-)	Bold International FZCO
5	15994	Sports Balls (Wall Balls) (Class-06)	Tempo Enterprises
<u>20-12-2011</u>			
6	15995	Finger Print Scanner Casing (Class-)	BIOMETRICSAXS
<u>21-12-2011</u>			
7	15996	Tile (Class004)	IBERO
8	15997	Tile (Class-04)	IBERO
9	15998	Tile (Class-04)	IBERO
<u>22-12-2011</u>			
10	15999	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
11	16000	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
12	16001	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
13	16002	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
14	16003	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
15	16004	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
16	16005	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
17	16006	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,

18	16007	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
19	16008	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
20	16009	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
21	16010	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
22	16011	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
23	16012	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
24	16013	Bottle (Class-03)	RECKITT & COLMAN (OVERSEAS) LIMITED,
<u>23-12-2011</u>			
25	16014	An Automobile (Class-)	Honda Motor Co., Ltd.

REGISTRATION OF DESIGNS

The following designs have been registered.

S. No.	Design No.	Title & Class	Inventor
<u>22-12-2011</u>			
1	15783	Water Cooler (Class-03)	Asif Zubair & Co
2	15784	Hot Pot (Class-03)	Asif Zubair & Co
3	15786	Water Cooler (Class-03)	Asif Zubair & Co
4	15787	Hot Pot (Class-03)	Asif Zubair & Co

(SABIR GUL)
 Controller of Patents
 & Registrar of Designs
Ph: 99215488